What the EFSA L-Theanine Ruling Means?

Industry

What Does The EFSA L-Theanine Ruling Mean?

Yes, a European regulator rejected the L-theanine focus claim. Then, in 2018, it approved a narrower one for caffeine. The full ruling, and what it lets an honest brand actually say.

If you’ve gone looking, you’ve probably already found the uncomfortable part: a European regulator looked at L-theanine and said no. People quote it to dismiss an entire category of drinks. They’re half right, and the half they get wrong is the half that matters.

So here is the full ruling, in plain terms — what was rejected, what was approved, and what an honest brand is allowed to say because of it. We’d rather you read this from us than find it later and assume we were hiding it.

First: who EFSA is, and why their no carries weight

EFSA is the European Food Safety Authority. Among other things, it decides which health claims a food or supplement is legally allowed to print. A company submits a claim and its evidence; a scientific panel reviews it; the claim is approved or refused. A refusal isn’t a marketing setback. It means the claim cannot be made at all.

That makes EFSA one of the few sources in this category you can actually lean on. They have no product to sell.

2011: the L-theanine cognition claim was rejected

In 2011, the panel reviewed the proposal that L-theanine, on its own, improves attention, concentration, and related thinking. It examined the studies. It rejected the claim.

Read that carefully, because the nuance is everything. EFSA did not rule that L-theanine is inert or harmful. It ruled that the evidence did not establish L-theanine as a cause of better thinking. Absence of proof, made official.

This is the sentence skeptics screenshot. And they should — it’s true. Any drink built on the idea that L-theanine alone sharpens your mind is standing on ground a regulator already declined to certify.

Absence of proof, made official.

2018: a different, narrower claim was approved

Seven years later, a separate claim cleared the panel. The approved wording, in essence: owing to its caffeine content, black tea improves attention. The approval came with a condition — the tea has to deliver at least 75 milligrams of caffeine for the claim to hold.

Two details decide how this can honestly be used.

First, the engine is caffeine, not L-theanine. The 2018 approval rests entirely on caffeine content. It is, quietly, the regulator confirming what the 2011 rejection implied: in the caffeine-plus-L-theanine pairing, the measurable attention effect traces back to the caffeine.

Second — and almost everyone gets this wrong — the approved wording names black tea specifically. That’s the tea that was studied and submitted. It does not automatically extend to oolong, pu-erh, or white tea. An honest brand selling those teas cannot copy EFSA’s exact sentence and pretend the regulator blessed its specific leaf. It has to paraphrase, and it has to be clear it’s paraphrasing: owing to its caffeine content, this tea improves attention at a high enough dose. The mechanism is the same caffeine; the wording stays inside what was actually approved.

We follow that boundary on purpose. When you see us describe the attention effect, it’s built on the caffeine the leaf delivers — the one part of this with a regulator’s signature on it — and worded so we’re never borrowing an approval that belongs to a different tea.

What about the calm? The 2025 evidence & honest concession

The other thing people hope L-theanine does is take the edge off. There’s a real signal here, and there’s a real limit, and we’ll give you both.

The most current synthesis — a 2025 review of fifty controlled trials — reached the same conclusion as the regulator: when caffeine and L-theanine improve attention together, that benefit is most likely attributable to the caffeine.

On stress specifically, the controlled trials show a single dose can lower a stress marker about an hour after you take it. Acute, measurable, repeatable. But here is the part we won’t step around: when researchers ran the same dose daily for twenty-eight days and measured the long game, the effect did not beat a placebo. The short-term calming is supported. The chronic, weeks-long stress reduction is not established.

So we don’t claim it. We won’t tell you a daily cup quietly lowers your baseline stress over a month, because the strongest study to test that came back null. What the leaf can honestly offer is better ride quality on the same caffeine — in the moment, not as a long-term promise.

Why this ruling is good news for you, not bad

Read fast, the EFSA story sounds like a takedown. Read fully, it’s a filter. It separates the brands that respect it from the brands that bury it.

Watch what most of the category does with this information: nothing. They keep selling “focus” on the back of a molecule that a regulator declined to certify, and they hide the actual doses inside a proprietary blend so you can’t check the math. One brand’s customer service, asked point-blank for its L-theanine dose, replied that disclosing it “would threaten the integrity of the brand.” Translation: the number wouldn’t survive your scrutiny.

If a dose is real and effective, you publish it. If you’re hiding it behind a blend name, you’re telling on yourself.

Our position is the inverse. Every tin lists what’s in it. Every harvest carries a third-party assay you can scan and read before you buy. We concede the 2011 rejection out loud, we stay inside the 2018 wording, and we name the limit on the calming claim. Not because regulation forces a blog post to do that — because the reader who reads EFSA rulings for fun is exactly the reader we want, and she can smell a dodge.

If a dose is real and effective, you publish it. If you’re hiding it behind a blend name, you’re telling on yourself.

Why we’d rather you read this from us

There’s a reason a tea company is writing an even-handed summary of a ruling that complicates its own marketing. The person who searches for an EFSA ruling on a Saturday morning is the most valuable reader in this category and the hardest to fool. She will find the 2011 rejection on her own. If she finds it before the brand has acknowledged it, every other claim on the page dies with it.

So we say it first. The cognition claim was rejected. The calming effect is short-term, and the month-long version of it failed against a placebo. The attention benefit is caffeine’s, the dose has to be real to count, and the approved wording belongs to a tea we don’t even sell. None of that is convenient. All of it is true — and a brand willing to print the inconvenient version first is the one worth reading to the end.

The 75-milligram condition is the real filter

Don’t read past the dose condition attached to the 2018 approval — it does more work than the claim itself. The attention benefit only holds at 75 milligrams of caffeine or more. That one number quietly disqualifies a large slice of the “coffee alternative” shelf.

Many of the powders and pods sold as coffee replacements come in well under that line — sometimes a third of it. Under the regulator’s own condition, they don’t reach the bar for the attention claim at all. So when a low-caffeine product borrows the language of focus, it’s leaning on an approval whose single firm requirement it doesn’t actually meet. The dose is the tell. The honest brands print it; ask the rest for it, and watch what happens.

How to read any tea or supplement claim from here

You can carry three quick tests to almost anything in this aisle.

First: Is the claim about caffeine, or about a fancier-sounding molecule? Caffeine has a regulator’s signature on it. Most of the rest — the mushrooms, the standalone amino acids, the proprietary “stacks” — is hope dressed as science.

Second: Is the dose printed, or buried in a blend? A dose that works gets published because publishing it sells the product. A dose that’s too small to matter gets folded into a “proprietary blend.” The hiding is the answer.

Third: Does the wording match the tea in the tin? An approval written for black tea is not an approval for oolong, pu-erh, or white. A brand that copies the exact sentence anyway is counting on you not to notice the swap.

Run those three tests, and the category sorts itself. The honest products pass all three. The rest fail on the one they were hoping you’d skip.

-> See Every Dose We Publish and the Science Underneath It

The Mechanism, In Three Tins

GET THE THREE-TIN PROTOCOL SET - $129 -